NS-2359

NS-2359

NS-2359 (pronunciation: en-es-two-three-five-nine) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by the Danish pharmaceutical company NeuroSearch for the treatment of major depressive disorder and cognitive impairment.

Etymology

The term "NS-2359" is a proprietary name given by the pharmaceutical company NeuroSearch. The "NS" stands for NeuroSearch, while "2359" is a unique identifier for the compound.

Pharmacology

NS-2359 works by inhibiting the reuptake of the neurotransmitters serotonin, norepinephrine, and dopamine, thereby increasing their availability in the brain. This mechanism of action is similar to that of other antidepressants, but NS-2359 affects all three neurotransmitters equally, which is not the case with most other drugs in this class.

Clinical Trials

NS-2359 has undergone Phase I and II clinical trials for the treatment of major depressive disorder and cognitive impairment. However, development was discontinued after the drug failed to meet the primary endpoints in a Phase II study.

Related Terms

• Serotonin-norepinephrine-dopamine reuptake inhibitor
• NeuroSearch
• Major depressive disorder
• Cognitive impairment
• Clinical trials
• Antidepressants
• Neurotransmitters
• Serotonin
• Norepinephrine
• Dopamine

External links

• Medical encyclopedia article on NS-2359
• Wikipedia's article - NS-2359

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski